MannKind Corporation to Hold 2021 Third Quarter Financial Results Conference Call on November 9, 2021
November 02 2021 - 6:05AM
MannKind Corporation (Nasdaq:MNKD) will release
its 2021 third quarter financial results and its management will
host a conference call to discuss the financial results and
corporate updates at 5:00 PM (Eastern Time) on Tuesday, November 9,
2021.
Presenting from the Company will be its Chief Executive Officer,
Michael Castagna and Chief Financial Officer, Steven B. Binder.
Those interested in listening to the conference call live via
the Internet may do so by visiting the Company's website at Events
& Presentations
https://investors.mannkindcorp.com/events-and-presentations.
A replay will also be available on MannKind's website for 14
days.
About MannKind CorporationMannKind Corporation
(Nasdaq: MNKD) focuses on the development and commercialization of
inhaled therapeutic products for patients with endocrine and orphan
lung diseases. MannKind is currently commercializing Afrezza®
(insulin human) Inhalation Powder, the Company’s first FDA-approved
product and the only inhaled ultra rapid-acting mealtime insulin in
the United States, where it is available by prescription from
pharmacies nationwide. Afrezza is also available by prescription in
Brazil, where it is commercialized by the Company’s partner, Biomm
SA. MannKind was established in 1991, and is headquartered in
Westlake Village, Calif., with a manufacturing and R&D facility
based in Danbury, Conn. The Company also employs field sales and
medical representatives across the U.S. Please visit
mannkindcorp.com to learn more.
MANNKIND CONTACT:Rose Alinaya, Investor
Relations Phone: (818) 661-5000 Email: ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jun 2024 to Jul 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jul 2023 to Jul 2024